Financial Comparison: Gadsden Properties (OTCMKTS:GADS) versus ENDRA Life Sciences (NASDAQ:NDRA)

ENDRA Life Sciences (NASDAQ:NDRA) and Gadsden Properties (OTCMKTS:GADS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Profitability

This table compares ENDRA Life Sciences and Gadsden Properties’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-127.39%	-103.77%
Gadsden Properties	N/A	N/A	N/A

Volatility and Risk

ENDRA Life Sciences has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Gadsden Properties has a beta of -5.57, meaning that its share price is 657% less volatile than the S&P 500.

Institutional & Insider Ownership

1.2% of ENDRA Life Sciences shares are held by institutional investors. 0.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 5.0% of Gadsden Properties shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares ENDRA Life Sciences and Gadsden Properties”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$10.06 million	($901.15)	-0.01
Gadsden Properties	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations for ENDRA Life Sciences and Gadsden Properties, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	0	0	1	0	3.00
Gadsden Properties	0	0	0	0	0.00

ENDRA Life Sciences presently has a consensus price target of $700,000.00, suggesting a potential upside of 14,435,866.18%. Given ENDRA Life Sciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than Gadsden Properties.

Summary

ENDRA Life Sciences beats Gadsden Properties on 5 of the 8 factors compared between the two stocks.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

About Gadsden Properties

Gadsden Properties, Inc. is a Nevada corporation that was formed on December 28, 2010. Gadsden concentrates primarily on investments in high quality income-producing assets, residential developments and other opportunistic commercial properties in secondary and tertiary markets across the United States. The Company derives value from smaller, flexible retail investments that range from $5 million to $50 million and off-market mixed-use properties ranging from $50 million to $250 million. As a result of this chosen strategy, we believe that Gadsden is developing a unique competitive advantage that generally allows the Company to invest in markets and assets that are often overlooked by larger institutional investors, such as publicly-traded REITs and other large institutional investors. As part of its strategy, Gadsden attracts specific sellers that prefer the tax deferral advantages offered through issuing operating partnership units in exchange for their properties. These real estate assets are typically operated by independent owners that are seeking to monetize their real estate holdings, and who are typically not well capitalized or well-seasoned real estate operators. These transactions create a variety of outcomes for Gadsden and the sellers typically resulting in lease-up and value-added opportunities that may not be otherwise achieved.